Subscribe
Home
Issues
2026
February 2026 - Vol 19 No 1
2025
November 2025 - Vol 18 No 4
August 2025 - Vol 18 No 3
May 2025 - Vol 18 No 2
February 2025 - Vol 18 No 1
2024
November 2024 - Vol 17 No 4
September 2024 - Vol 17 No 3
May 2024 - Vol 17 No 2
February 2024 - Vol 17 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ASCO 2025 - Small Cell Lung Cancer
ONS 2025 - Endometrial Cancer
Web Exclusives
Case-Based Exchanges
Evolving Landscapes in Multiple Myeloma
OFS Summit
Drug Updates
Videos
Interview with the Innovators
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Master Class Series
Ask the Experts
Advanced Endometrial Cancer Education
Resources
Quick Quiz
Articles
Articles
New Developments in the Management of Hand-Foot Syndrome Associated With Oral Anti-VEGF Tyrosine Kinase Inhibitor–Targeted Anticancer Therapies
By
Joanna Schwartz, PharmD, BCOP
;
Shannon Hogan, PharmD
Supportive Care
TON - April 2013, Vol 6, No 3
Hand-foot skin reaction (HFSR), also known as hand-foot syndrome or palmar-plantar erythrodysesthesia (PPE), is an adverse effect of several chemotherapeutic agents.
Read More ›
From the Editor
By
Beth Faiman, PhD, APRN-BC, AOCN
From the Editor
TON - April 2013, Vol 6, No 3
This issue of The Oncology Nurse-APN/PA (TON) is packed with news about what is happening in the world of oncology research and brings you information that helps you in your day-to-day practice. We highlight news from the 2013 Genitourinary Cancers Symposium and the Hematology/Oncology Pharmacy Association (HOPA) 9th Annual Conference.
Read More ›
Testicular Cancer
Noteworthy Numbers
TON - April 2013, Vol 6, No 3
Testicular cancer, or testis cancer, is most often found in young men. With the use of surgery, radiation therapy, and/or chemotherapy, this type of cancer is highly treatable, and it is often curable.
Read More ›
Deviation From Clinical Guidelines Takes Toll on Ovarian Cancer Survival
By
Charles Bankhead
Gynecologic Cancers
TON - April 2013, Vol 6, No 3
According to a retrospective review of more than 13,000 cases, most women with ovarian cancer received substandard care that significantly reduced their survival odds.
Read More ›
Reduced Mortality Attributed to Nurse Staffing at Magnet Hospitals
TON - Daily
Researchers report that better nurse staffing, education, and work environment partially account for lower mortality and other improved patient outcomes at hospitals certified in the Magnet Recognition Program®.
Read More ›
Cardiovascular Disease Risk High for Breast Cancer Survivors
TON - Daily
Researchers surveyed survivors of breast, colorectal, gynecologic, and prostate cancers and found that when compared with the general adult population, cancer survivors have increased cardiovascular disease risk factors.
Read More ›
ACS: Organized Efforts Necessary to Transform Cancer Risk Behaviors
TON - Daily
Challenges prevail in the US population when it comes to transforming behaviors and risk factors related to cancer death.
Read More ›
Breast Cancer Mortality Greater for Black Women
TON - Daily
When compared with other racial and ethnic groups across cancer subtypes, black women with breast cancer have significantly poorer survival, according to a recent study.
Read More ›
Genetic Code May Predict Chemotherapy Side Effects
TON - Daily
In the first study of its kind to examine the human genome for predictors of chemotherapy side effects, researchers isolated gene variations with the potential to cause chemotherapy-induced peripheral neuropathy in patients.
Read More ›
Mammography Screening Delay Increases Mortality in Older Women
TON - Daily
According to recent study results, women aged 75 years and older were at an increased risk for breast cancer mortality when an extended period of time existed between their last mammogram and a breast cancer diagnosis.
Read More ›
Page 250 of 376
247
248
249
250
251
252
253
View the Latest Issue of TON
Read Issue
Home
Issues
2026
February 2026 - Vol 19 No 1
2025
November 2025 - Vol 18 No 4
August 2025 - Vol 18 No 3
May 2025 - Vol 18 No 2
February 2025 - Vol 18 No 1
2024
November 2024 - Vol 17 No 4
September 2024 - Vol 17 No 3
May 2024 - Vol 17 No 2
February 2024 - Vol 17 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ASCO 2025 - Small Cell Lung Cancer
ONS 2025 - Endometrial Cancer
Web Exclusives
Case-Based Exchanges
Evolving Landscapes in Multiple Myeloma
OFS Summit
Drug Updates
Videos
Interview with the Innovators
Rapid Reactions
Best Practices in Breast Cancer Therapy | OFS
Master Class Series
Ask the Experts
Advanced Endometrial Cancer Education
Resources
Quick Quiz
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION